Cargando…

Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies

Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has shown remarkable results in regression of the size of tumors in NSCLC and has shown survival advantage. However, immune-related adverse effects are a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudry, Abdul, Chaudry, Misbat, Aslam, Jonaid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386084/ https://www.ncbi.nlm.nih.gov/pubmed/32754380 http://dx.doi.org/10.7759/cureus.8836

Ejemplares similares

Celiac Disease and the Autoimmune Web of Endocrinopathies
por: Sange, Ibrahim, et al.
Publicado: (2020)

TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient
por: Miatech, Jennifer L, et al.
Publicado: (2019)

Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis
por: Balti, Eric, et al.
Publicado: (2022)

Hypothyroidism and diabetes mellitus – a risky dual gestational endocrinopathy
por: Tirosh, Dan, et al.
Publicado: (2013)

Pembrolizumab-Induced Hypothyroidism: A Case Report
por: Gaibor, Carlos, et al.
Publicado: (2023)

LBSAT236 A Case of Immune Checkpoint Inhibitor Pembrolizumab Induced Simultaneous Rare Endocrinopathies, Type 1 DM (presenting As DKA) And Grave's Thyrotoxicosis, With Evidence Of Autoimmunity Development.
por: Arora, Gunjan, et al.
Publicado: (2022)

A Rare Case of Pembrolizumab-Associated Graves’ Disease
por: Alqaisi, Sura, et al.
Publicado: (2023)

Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia
por: Baldawi, Muaamar B, et al.
Publicado: (2022)

Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case
por: Sankar, Keerthana, et al.
Publicado: (2021)

Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
por: Zilberman, Stephanie, et al.
Publicado: (2023)

Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy
por: Hernandez, Andrea, et al.
Publicado: (2021)

Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen
por: Figueroa-Perez, Nikole, et al.
Publicado: (2021)

A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma
por: Salangsang, Jonathan, et al.
Publicado: (2023)

Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event
por: Doodnauth, Andrew V, et al.
Publicado: (2021)

New-Onset Autoimmune Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Association With Pembrolizumab Therapy and Long Term Follow-Up: Case Report
por: Pachpande, Vrushali, et al.
Publicado: (2022)

Perception and Management of Obesity Among Pakistani Doctors
por: Butt, Farooq, et al.
Publicado: (2019)

Thyrotoxic Muscle Paralysis as a Rare Cause of Reversible Muscle Weakness: A Case Report
por: Iqbal, Qasim Z, et al.
Publicado: (2020)

Frequency of Retinopathy in Patients Newly Diagnosed With Type 2 Diabetes Mellitus
por: Khan, Wagmah Javed, et al.
Publicado: (2023)

Diabetic Foot Ulcers and Their Surgical Management: Our Experience at Hayatabad Medical Complex, Peshawar
por: Aslam, Rashid, et al.
Publicado: (2023)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022)

Subacute Thyroiditis Causing Fever of Unknown Origin: A Reminder of the Uncommon Cause
por: Lee, Sin Yin, et al.
Publicado: (2023)

An Unusual Cause of Refractory Hypothyroidism
por: Mirgoli, Omead J, et al.
Publicado: (2022)

Adherence to Hypoglycemic Agents in Type 2 Diabetes Mellitus: A Cross-Sectional Study
por: Khayyat, Yara A, et al.
Publicado: (2022)

Primary Amenorrhea With Hypothyroidism: Finding the Cause
por: Alvi, Asim Munir, et al.
Publicado: (2021)

An Unrecognized Cause of Elevated Procalcitonin Level
por: Thiab, Ghadah, et al.
Publicado: (2023)

Severe Refractory Hypocalcemia Caused by Denosumab
por: Dadana, Sriharsha, et al.
Publicado: (2023)

The Long-Term Use of Methotrexate Monotherapy as a Steroid-Sparing Agent for Patients With Pulmonary Sarcoidosis
por: Baiyasi, Ahmad F, et al.
Publicado: (2021)

Seizures and Basal Ganglia Calcification Caused by Hypoparathyroidism
por: Nageen, Tabinda, et al.
Publicado: (2020)

Conn’s Syndrome: An Unusual Cause of Periodic Paralysis
por: Balhana, Sílvia, et al.
Publicado: (2022)

Thyrotoxic Periodic Paralysis: An Unusual Cause of Quadriparesis
por: Kaeley, Nidhi, et al.
Publicado: (2022)

Three Cases of Lactic Acidosis Caused by Biguanides
por: Kuwahara, Masaatsu, et al.
Publicado: (2022)

Erroneous Causes of Point-of-Care Glucose Readings
por: Majewski, Joseph, et al.
Publicado: (2023)

Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review
por: Iqbal, Shumaila M, et al.
Publicado: (2019)

Gastrointestinal Neuroendocrine Tumor, Colon Adenocarcinoma, and Hyperparathyroidism: An Unorthodox Synchronism
por: Aslam, Hafiz M, et al.
Publicado: (2018)

Generalized Edema Caused by Albiglutide: A Case Report
por: Aziz, Kashif, et al.
Publicado: (2018)

Hypothyroidism Causing Pericardial Effusion: A Case Report
por: Mirwais, Sabawoon, et al.
Publicado: (2019)

Diabetic Ketoacidosis: Possible Cause of Thrombotic Thrombocytopenic Purpura
por: Jackson, Logan J, et al.
Publicado: (2021)

Chronic Steroid Use Causing Spinal Epidural Lipomatosis
por: Alnabwani, Dina, et al.
Publicado: (2022)

Primary Hyperparathyroidism Causing Psychosis: A Case Report
por: Meng, Aaron Z, et al.
Publicado: (2022)

Bexarotene: A Rare Cause of Misleading Thyroid Function Tests
por: Pattan, Vishwanath, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96u0rcpjd4nr1kj5bmjiaccjg6